Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

5.050 USD -0.080 (-1.56%)
Official Closing Price Updated: 7:59 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Adaptimmune Ther Ads

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global... 
From GlobeNewswire News Releases
BRIEF-Adaptimmune Q1 revenue $2.9 million versus $2.7 million
* Q1 revenue $2.9 million versus $2.7 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780) 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Q1 revenue $2.9 million versus $2.7 million
* Adaptimmune therapeutics plc qtrly loss per share $0.04 per ordinary share 
Tags companyNews
From Reuters: Company News
Adaptimmune Reports First Quarter 2016 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2016. 
From GlobeNewswire News Releases
Hottest Manufacturing Stocks Now – NBY PRCP RGNX KURA
 
Tags NASDAQ:CERC NASDAQ:ENDP NASDAQ:RGNX
From InvestorPlace
Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Bank of... 
From GlobeNewswire News Releases
Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present... 
From GlobeNewswire News Releases
Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted an Investor and Analyst meeting in New York and presented clinical and... 
From GlobeNewswire News Releases
Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide... 
From GlobeNewswire News Releases
Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology... 
From GlobeNewswire News Releases
Adaptimmune to Host Analyst and Investor Day on April 22, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company will host a live webcast in conjunction with its 2016... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics Reveals Wenyong Wang Joining As VP Of Business Development
Adaptimmune Therapeutics PLC (NASDAQ: ADAP) disclosed Wenyong Wang has joined the company as its VP of Business Development. The ... 
Tags Management ADAP Benzinga
From Benzinga
Adaptimmune Announces New Vice President of Business Development, Wenyong Wang
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that Dr. Wenyong Wang has joined the company as Vice President of... 
From GlobeNewswire News Releases
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the... 
From GlobeNewswire News Releases
BRIEF-Adaptimmune Therapeutics says FDA grants orphan drug designation to its t-cell therapy
* U.S. Food and drug administration grants orphan drug designation to adaptimmune's t-cell therapy targeting ny-eso for treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:... 
Tags companyNews
From Reuters: Company News
U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan... 
From GlobeNewswire News Releases
How To Profit On The $200 Billion Immunotherapy Market
Wall Street concurs. According to Allied Market Research, the immuno-oncology market has been growing at a solid 7.1% annual clip since 2014, and it's expected to hit $110 billion by 2020. 
Tags Pharma/Biotech Healthcare Stocks / Equities
From Blogs - TalkMarkets
Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the six-month period ended... 
From GlobeNewswire News Releases
Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present... 
From GlobeNewswire News Releases
Hottest Manufacturing Stocks Now – ARDM OHRP EFOI NMBL
 
Tags NYSE:WLK NASDAQ:WATT NASDAQ:GNCA
From InvestorPlace
Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present... 
From GlobeNewswire News Releases
Biggest Movers in Manufacturing Stocks Now – COLL EDGE ASMB HPJ
 
Tags NASDAQ:OASM NYSE:WAB Hot Stocks
From InvestorPlace
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted... 
From GlobeNewswire News Releases
Adaptimmune to Participate in Two Upcoming Investor Conferences
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present... 
From GlobeNewswire News Releases
Biggest Movers in Manufacturing Stocks Now – VBLT KORS LOJN FN
 
Tags NASDAQ:LOJN NYSE:AXON NYSE:AGCO
From InvestorPlace
Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT)... 
From GlobeNewswire News Releases
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) today announced that... 
From GlobeNewswire News Releases
Adaptimmune Announces New Additions to Manufacturing Senior Management
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for... 
From GlobeNewswire News Releases
10 biotech stocks to buy at ‘silly’ cheap prices
The industry is healthier than ever, and three main concerns don’t pan out, writes Michael Brush. 
Tags AMGN Biotechnology BBC
From MarketWatch
Biggest Movers in Manufacturing Stocks Now – TTNP JAGX LPTH CTMX
 
Tags Hot Stocks NASDAQ:ATRA NASDAQ:TTNP
From InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.